Article Figures & Data
Figures
- FIGURE 1.
Study design. CRT = chemoradiotherapy.
- FIGURE 2.
Kaplan–Meier analysis of PFS at median cutoff in ΔTLG. Median, 1-y, and 2-y PFS was 15.9 mo, 73%, and 40%, respectively, for ΔTLG decrease ≥ 45% vs. 9.8 mo, 46%, and 0%, respectively, for ΔTLG decrease < 45% (log-rank test, P = 0.032).
- FIGURE 3.
Kaplan–Meier analysis of favorable, intermediate, and unfavorable risk groups (log-rank test, P < 0.02).
- FIGURE 4.
Typical example of 2 patients with stage III NSCLC and their sequential 18F-FDG PET/CT scans: pretreatment (D0), in-treatment (D15), and end of treatment (D66). Two weeks into concomitant chemoradiotherapy, patient A showed 14% decrease in in-treatment SUV, and 54% decrease in TLG, censored for both overall survival and PFS at 19 mo. Patient B showed 14% decrease in in-treatment SUV and TLG, PFS of 12 mo, and overall survival of 16 mo. All series are shown using equal window scaling.
Tables
Characteristic Value Age (y) Mean 59 Range 41−77 Age < 65 15 (54%) Age ≥ 65 13 (46%) Sex Male 18 (64%) Female 10 (36%) Histology Squamous cell carcinoma 11 (39%) Adenocarcinoma 14 (50%) Non–small cell (not otherwise specified) 3 (11%) TNM stage (sixth edition) IIIA 17 (61%) T0N2 1 (4%) T1N2 3 (11%) T2N2 8 (29%) T3N2 5 (18%) IIIB 11 (39%) T1N3 3 (11%) T2N3 1 (4%) T4N0 3 (11%) T4N2 2 (7%) T4N3 2 (7%) Performance score (ECOG) 0 20 (71%) 1 8 (29%) Smoking status Current smoker 12 (43%) Former smoker 16 (57%) Previous malignancy No 24 (86%) Yes 4 (14%) Adjuvant surgery No surgery 20 (71%) Lobectomy 8 (29%) TNM stage (sixth edition) n Pretreatment TLG In-treatment TLG ΔTLG (%) IIIA (n = 17) T0N2 1 (4) 83.60 26.93 −67.79 T1N2 3 (11) 27.35 15.34 + 43.91 127.97 108.18 −15.46 6.33 3.27 −48.31 T2N2 8 (29) 156.81 59.93 −61.78 323.93 278.08 −14.16 199.1 48.63 −75.57 31.83 30.05 −5.59 60.21 76.13 +26.45 92.89 51.88 −44.15 72.18 45.47 −37.00 243.41 92.01 −62.20 T3N2 5 (18) 188.80 145.7 −22.83 339.14 68.61 −79.77 95.80 64.47 −32.70 233.48 108.07 −53.71 717.87 624.52 −13.00 IIIB (n = 11) T1N3 3 (11) 263.68 398.50 +51.13 49.79 20.44 −58.94 163.20 74.16 −54.56 T2N3 1 (4) 224.42 84.67 −62.27 T4N0 3 (11) 77.19 36.98 −52.10 199.84 26.00 −86.99 676.20 416.06 −38.47 T4N2 2 (7) 489.18 174.15 −64.40 1319.04 1042.25 −20.98 T4N3 2 (7) 339.64 177.56 −47.72 210.71 152.9 −27.43 Data in parentheses are percentages.
PET parameter HR 95% confidence interval P Pretreatment TLG 1.005 1.002–1.007 0.004 In-treatment TLG 1.005 1.003–1.008 0.001 ΔTLG 1.016 1.002–1.030 0.025 Pretreatment SUV Not significant 0.999–1.002 0.575 In-treatment SUV Not significant 0.999–1.003 0.327 ΔSUV Not significant 0.995–1.022 0.231 Pretreatment SUVmax Not significant 0.999–1.000 0.447 In-treatment SUVmax Not significant 0.999–1.002 0.579 ΔSUVmax Not significant 0.998–1.027 0.087 TNM (IIIA–IIIB) Not significant 0.299–2.136 0.655 PET parameter HR 95% confidence interval P ΔTLG 1.169 1.013–1.350 0.033 Pretreatment TLG 1.047 1.020–1.076 0.009 PFS Median PFS (mo) 1-y PFS (%) 2-y PFS (%) P All patients 15.7 76 28 ΔTLG decrease < 38% (n = 12) 6.3 36 0 0.020 ΔTLG decrease ≥ 38% (n = 16) 15.9 80 33 ΔTLG decrease < 45% (n = 14) 9.8 46 0 0.032 ΔTLG decrease ≥ 45% (n = 14) 15.9 73 40 ΔTLG decrease < 52% (n = 16) 9.8 47 0 0.035 ΔTLG decrease ≥ 52% (n = 12) 17.1 82 44
Jump to section
Related Articles
Cited By...
- Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity During Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prospective Cohort Study
- The Predictive Value of Early In-Treatment 18F-FDG PET/CT Response to Chemotherapy in Combination with Bevacizumab in Advanced Nonsquamous Non-Small Cell Lung Cancer
- 18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response
- 18F-FDG PET/CT: Therapy Response Assessment Interpretation (Hopkins Criteria) and Survival Outcomes in Lung Cancer Patients
- Can an 18F-ALF-NOTA-PRGD2 PET/CT Scan Predict Treatment Sensitivity to Concurrent Chemoradiotherapy in Patients with Newly Diagnosed Glioblastoma?
- Imaging-Based Treatment Adaptation in Radiation Oncology
- Predicting Survival in Non-Small-Cell Lung Cancer Using Positron Emission Tomography: Several Conclusions From Multiple Comparisons